Is Vascepa Safe with ACE Inhibitors?
Vascepa (icosapent ethyl), a purified EPA omega-3 for reducing cardiovascular risk, shows no major contraindications with ACE inhibitors like lisinopril or enalapril. Clinical data from the REDUCE-IT trial, which tested Vascepa in high-risk patients (many on antihypertensives including ACE inhibitors), reported no significant interaction signals.[1] Real-world use aligns, with combination therapy common in cardiovascular patients without routine warnings in prescribing info.[2]
What Do Drug Interaction Checkers Say?
Tools like Drugs.com and Lexicomp rate Vascepa-ACE inhibitor combos as low-risk (no known interactions).[3][4] No pharmacokinetic clashes—Vascepa doesn't inhibit CYP enzymes or affect ACE inhibitor metabolism. Labels for both classes omit mutual warnings.[2][5]
Potential Risks to Watch
Minor concerns exist:
- Bleeding: Vascepa mildly boosts bleeding risk (via antiplatelet effects); ACE inhibitors can too in some cases. Risk stays low unless paired with anticoagulants.[1][6]
- Blood pressure: Vascepa may slightly lower BP (1-2 mmHg in trials); ACE inhibitors do the same, but no hypotensive synergy reported.[1]
Monitor for bruising, hypotension, or renal changes, especially in elderly or kidney-impaired patients. No dose adjustments needed.[2]
What REDUCE-IT Data Shows on Combinations
Over 8,000 patients, 70%+ took antihypertensives (including ACE inhibitors). Vascepa cut CV events 25% with no excess adverse events vs. placebo in combo users.[1] Post-hoc analyses confirm safety in polypharmacy settings.[7]
Patient Experiences and Doctor Advice
Forums like Reddit and Drugs.com reviews note smooth combos, with rare complaints of fatigue or GI upset (unlinked to interaction).[8] Cardiologists often prescribe together for statin-intolerant CVD patients. Always check with your doctor—individual factors like dose, kidney function, or other meds matter.[2]
Alternatives if Concerned
If avoiding combo, consider:
- Statins (e.g., atorvastatin) over Vascepa for lipid control.
- ARBs (losartan) instead of ACE inhibitors—similar profile, potentially fewer cough issues.[9]
No generics for Vascepa yet; patent expires ~2027 (check DrugPatentWatch.com for updates).[10]
[1] https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[2] https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/202057s019lbl.pdf
[3] https://www.drugs.com/drug-interactions/vascepa-with-lisinopril-3318-0-1476-0.html
[4] https://online.lexicomp.com
[5] https://www.accessdata.fda.gov/drugsatfdadocs/label/2019/019777s039lbl.pdf (lisinopril example)
[6] https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044056
[7] https://www.jacc.org/doi/10.1016/j.jacc.2020.09.039
[8] https://www.drugs.com/comments/icosapent-ethyl/vascepa.html
[9] https://www.uptodate.com/contents/choice-of-drug-therapy-in-primary-essential-hypertension
[10] https://www.drugpatentwatch.com/p/tradename/VASCEPA